This site is intended for health professionals only!

Published on 2 July 2007

Share this story:

Genmab regains lymphoma drug rights


It is normally a sign of bad news but Genmab says it is delighted that Merck KGaA has returned the rights to a new lymphoma drug to the Denmark-based drugmaker.

Genmab has regained all rights to the HuMax-CD4

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine